Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-24

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of T-1201 injection in subjects with advanced solid tumors refractory to standard therapy, or for whom no standard therapy is available. The main questions it aims to answer are:

* The Maximum tolerated dose (MTD) of T-1201 on different dosing schedules.
* The Recommended Phase 2 dose (RP2D) of T-1201 on different dosing schedules.

Researchers will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of T-1201.

Participants will:

Received T-1201 either once every 4 (Part A)/2 (Part B)/3 (Part C) weeks, depend on they participate in which parts of study.

Visit the clinic once every 2/3 weeks for checkups and tests

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

NCT05156203

Advanced Solid Tumor Lymphoma

RECRUITING PHASE1

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

NCT04830501

Advanced Solid Tumors

COMPLETED PHASE1

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

NCT04678921

Solid Tumor Metastatic Cancer Advanced Cancer

COMPLETED PHASE1

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

NCT03349073

Advanced Refractory Solid Tumors

COMPLETED PHASE1

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

NCT06403436

Advanced Solid Tumor Adult Solid Tumor Adult Disease +5 more

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T-1201 Injection 100 mg Kit

T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks (Part A), 2 weeks (Part B) or 3 weeks (Part C). T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.

Group Type EXPERIMENTAL

T-1201 Injection 100 mg Kit

Intervention Type DRUG

T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

T-1201 Injection 100 mg Kit

T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must meet all of the following criteria to be eligible for enrollment in the study:

1. Signed and dated informed consent form.
2. Histologically and cytologically confirmed advanced malignancies that are refractory to standard therapy or have no accepted standard therapy.
3. Solid tumors that are measurable or evaluable as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion).
4. Female or male, 20 years of age or older.
5. ECOG performance status 0 or 1.
6. QTcF ≤ 470 ms at screening.

Exclusion Criteria

Subjects presenting with any of the following will not be included in the study:

1. Clinically significant comorbidity such as unstable angina, congestive heart failure (NYHA Grade III or IV), uncontrolled hypertension (\>160/100 mmHg despite optimal medical treatment), chronic obstructive pulmonary disease (COPD) with frequent exacerbations, refractory asthma, inflammatory bowel disease or intestinal obstruction.
2. Acute myocardial infarction or cerebrovascular accident (CVA) within 6 months prior the first dose of study drug.
3. Central nervous system (CNS) metastasis or seizure disorder due to underlying malignancy except those who have been treated and have stable CNS metastases or are asymptomatic.
4. AIDS-defining opportunistic infections within the past 12 months.
5. HBV infection (positive HBsAg) except for carrier of inactive HBV as defined by negative HBeAg with normal ALT and HBV DNA \< 2,000 IU/mL or HCV infection (positive anti-HCV antibody) except for those with undetectable HCV RNA.
6. Inadequate bone marrow reserve, hepatic or renal function as defined by any of the following laboratory values:

1. absolute neutrophil count (ANC) \< 1500/µL
2. platelet count \< 100 x 10\^9 /µL
3. hemoglobin \< 9 g/dL
4. total bilirubin \> 1.5 x the upper limit of normal (ULN)
5. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x ULN if no hepatic metastases are present; \> 5 x ULN if hepatic metastases are present
6. Estimated (Cockroft-Gault formula) creatinine clearance (CrCl) \< 60 mL/min CrCl = \[(140 - age (year)) x weight (kg)\] / (serum creatinine x 72) (x 0.85 for females)
7. Toxicities resulting from prior therapy or surgical procedures not yet resolved to ≤ NCI CTCAE v5.0 Grade 1 with the exception of alopecia, skin hyperpigmentation or hypopigmentation.
8. Major surgical procedures (as defined by Investigator) within 4 weeks prior to the first dose of study drug or any ongoing post-operative complications.
9. Receiving any (investigational or approved) anti-cancer therapy (including chemotherapy or targeted therapy) within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
10. A history of apparent allergic reactions to irinotecan, Tween 80 (dosed with prior treatment with prophylactic drug), and/or ethanol.
11. If female, is pregnant or breastfeeding.
12. If men or women with childbearing potential, unwilling to use effective contraceptive methods during the study and for at least 3 months (men) or 1 month (women) after the last dose of study drug. Effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.
13. Receiving live attenuated vaccine within 28 days prior to the first dose of study drug.
14. Life expectancy \< 3 months
15. Other prior or ongoing condition(s) that, in Investigator's opinion, could affect the safety of the subject, compromise the subject's ability to comply with the study requirements or impair the assessment of study results.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No